BetterLife Pharma Inc. announced that it has engaged Equilab International to manage the upcoming clinical trials for its proprietary formulation of Interferon alpha2b (AP-003) in mild to moderate cases of COVID-19. BetterLife believes that its inhaled IFN-a2b, AP-003, could lessen the severity and duration of COVID-19 and decrease the need for hospital admissions. Equilab is an internationally recognized CRO with a strong team of clinical and analytical researchers that have already conducted clinical trials in COVID-19 patients. BetterLife and Equilab will conduct the placebo-controlled blinded trials in COVID-19 patients at Equilab’s own 75 bed clinical facility.